No Data
No Data
Subdued Growth No Barrier To Guangxi Hechi Chemical Co., Ltd (SZSE:000953) With Shares Advancing 35%
Guangxi Hechi Chemical (000953.SZ): has repurchased 0.24% of the shares.
On September 2nd, Guangxi Hechi Chemical (000953.SZ) announced that as of August 31, 2024, the company had repurchased 878,100 shares through a dedicated securities account for stock repurchases in a centralized bidding trading method, accounting for 0.24% of the company's total share capital. The highest fill price for the purchased shares was 2.64 yuan/share, and the lowest fill price was 2.47 yuan/share, with a total transaction amount of 2,239,646.00 yuan (excluding transaction fees). The implementation of the share repurchase by the company complies with relevant laws and regulations and is in line with the established plan. As of September 2, 2024, the closing price of the company's stocks was 3 yuan.
Guangxi Hechi Chemical: Half-year report for the year 2024.
Guangxi Hechi Chemical: Summary of Half-Year Report in 2024.
Guangxi Hechi Chemical (000953.SZ): The net income for the first half of the year was 2.6368 million yuan, an increase of 639.30% compared to the same period last year.
Guangxi Hechi Chemical (000953.SZ) released its semi-annual report for 2024, with operating revenue of 0.128 billion yuan, a year-on-year increase of 15.11%; net profit attributable to shareholders of listed companies was 2.6368 million yuan, a year-on-year increase of 639.30%; net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses was 2.5409 million yuan, a year-on-year increase of 366.81%; basic earnings per share was 0.0072 yuan.
Guangxi Hechi Chemical (000953.SZ) and its subsidiary have not invested in the Sichuan Nansong Biomedical Manufacturing Base project.
On August 14th, Gelunhui reported that Guangxi Hechi Chemical (000953.SZ) stated on the investor interaction platform that as of now, the company and its subsidiaries have no investment in the Sichuan Nansong Biomedical Manufacturing Base project. The investment situation of the company's subsidiaries and external investments has been disclosed in the periodic report.
No Data
No Data